ROIV | Roivant Sciences Ltd. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	11.13 - 11.38
52 Week Range	9.69 - 13.06
Beta	1.33
Implied Volatility	36.56%
IV Rank	51.66%
Day's Volume	4,203,756
Average Volume	4,759,175
Shares Outstanding	727,950,000
Market Cap	8,203,996,500
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-12-08

Valuation
Profitability
Growth
Health
P/E Ratio	2.03
Forward P/E Ratio	N/A
EPS	5.54
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	908
Country	UK
Website	ROIV

Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.

ROIV's peers: MRVI, KRYS, RXDX, AKRO, APLS, DAWN, PHAT, BPMC, LYRA, CGEM, ASND, BGNE, PLRX, SNDX, RVMD, VRDN, INZY, ZLAB

*Chart delayed

Analyzing fundamentals for ROIV we got that it has weak fundamentals where Valuation is considered to be overvalued, Profitability is very wealthy, Growth is desperately bad and Health is weak. For more detailed analysis please see ROIV Fundamentals page.

Watching at ROIV technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on ROIV Technicals page.